Month: January 2020

The Quick Spread of Coronavirus is Impacting Global Economies and Markets

Posted on by Admin

The Quick Spread of Coronavirus is Impacting Global Economies and Markets

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

The coronavirus, first identified on December 31, has killed 81 people in China and infected more than 2,800 worldwide including five in the United States.  Coronavirus is an animal virus that has evolved to infect people.  It is constantly adapting and mutating making controlling the outbreak a challenge.  It can be spread between people not unlike the Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) viruses.   Given the rapid escalation of reported infections, the virus has the potential to spread to a point where it has an impact on companies involved in travel, vacation and health care.  Further escalation could even impact the economic growth rate of China and its trading partners.  World health officials are scrambling to contain the spread of the coronavirus.  But are officials prepared to contain the spread of the impact of the virus on the world’s economies?

Research – Dyadic International Inc. (DYAI) – C1 Technology’s Potential to Manufacture Candidate Vaccines Against Coronavirus

Posted on by Admin

Wednesday, January 29, 2020

Dyadic International Inc. (DYAI)

C1 Technology’s Potential to Manufacture Candidate Vaccines Against Coronavirus

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Rapidly growing epidemic and concerns on coronavirus outbreak. The deadly new virus, coronavirus, is a fast-growing epidemic in China. The number of confirmed cases increased from 2,835 on Monday (January 27) to 4,515 on Tuesday (January 28), according to the National Health Commission, jumping nearly 60 percent overnight. Epidemic is now expanding to other countries, including the United States. There are currently five cases in the U.S.

Potential higher rate of spread, but less deadly than SARS. Severe acute respiratory syndrome (SARS) is a related infectious disease, which erupted in China in 2002 and spread globally in 2003. SARS killed about 10% of the people it infected, while thus far coronavirus has killed about 3% of those infected. There are many unknowns regarding this new deadly strain of coronavirus; however,…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Great Panther Mining Limited (GPL) – Exploration Activity in Mexico Carries Momentum into 2020

Posted on by Admin

Wednesday, January 29, 2020

Great Panther Mining Limited (GPL)

Exploration Activity in Mexico Carries Momentum into 2020

Great Panther Mining Limited, headquartered in Vancouver, Canada, is a precious metals mining and exploration company that operates three mines. These include: 1) the Tucano gold mine in Amapa State, Brazil, 2) the Guanajuato mine complex which includes the Guanajuato and San Ignacio mines in Mexico, and 3) the Topia mine in Mexico. Great Panther also owns the Coricancha Mine in Peru, which is expected to restart operations in 2020. The shares are traded under the ticker “GPR” on the Toronto Stock Exchange and under the ticker “GPL” on the NYSE American.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Investing in Mexico. While attention in 2019 largely focused on the company’s Tucano mine in Brazil, Great Panther executed a successful exploration program in Mexico that set the stage for 2020. Following 21,711 meters of drilling in 2019, the company has allocated $4 million to fund exploration in Mexico in 2020, focused mainly on the Guanajuato and San Ignacio mines. The 2020 drilling program calls for 14,400 meters of drilling at the Guanajuato mine, up to 8,500 meters of drilling at the San Ignacio mine and 2,500 meters at Topia.

Guanajuato mine could resume production in 2020. At the beginning of 2019, production was suspended at the Guanajuato mine in order to focus on exploration for higher grade resources. Three rigs completed 8,832 meters of drilling in 126 holes and…


Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research dyadic international inc- dyai c1 technologys potential to manufacture candidate vaccines against coronavirus

Posted on by Admin

Wednesday, January 29, 2020

Dyadic International Inc. (DYAI)

C1 Technology’s Potential to Manufacture Candidate Vaccines Against Coronavirus

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Rapidly growing epidemic and concerns on coronavirus outbreak. The deadly new virus, coronavirus, is a fast-growing epidemic in China. The number of confirmed cases increased from 2,835 on Monday (January 27) to 4,515 on Tuesday (January 28), according to the National Health Commission, jumping nearly 60 percent overnight. Epidemic is now expanding to other countries, including the United States. There are currently five cases in the U.S.

Potential higher rate of spread, but less deadly than SARS. Severe acute respiratory syndrome (SARS) is a related infectious disease, which erupted in China in 2002 and spread globally in 2003. SARS killed about 10% of the people it infected, while thus far coronavirus has killed about 3% of those infected. There are many unknowns regarding this new deadly strain of coronavirus; however,…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Long Story Short: The Economic Symptoms from Epidemics Have Been Felt Before

Posted on by Admin

The Quick Spread of Coronavirus is Impacting Global Economies and Markets

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

The coronavirus, first identified on December 31, has killed 81 people in China and infected more than 2,800 worldwide including five in the United States.  Coronavirus is an animal virus that has evolved to infect people.  It is constantly adapting and mutating making controlling the outbreak a challenge.  It can be spread between people not unlike the Severe Acute Respiratory Syndrome (SARS) or Middle East Respiratory Syndrome (MERS) viruses.   Given the rapid escalation of reported infections, the virus has the potential to spread to a point where it has an impact on companies involved in travel, vacation and health care.  Further escalation could even impact the economic growth rate of China and its trading partners.  World health officials are scrambling to contain the spread of the coronavirus.  But are officials prepared to contain the spread of the impact of the virus on the world’s economies?

Research trovagene trov emerging as a leader in race to develop kras inhibitor

Posted on by Admin

Tuesday, January 28, 2020

Trovagene (TROV)

Emerging as a Leader in Race to Develop KRAS Inhibitor

Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.

Cosme Ordonez, Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are resuming coverage of Trovagene after reassigning research coverage to a different analyst. The company yesterday released interim results from a Phase II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (CRC) patients carrying KRAS mutations. Onvansertib is an inhibitor of PLK1. In experimental models, the drug kills cancer cells harboring KRAS mutations…

Results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held in San Francisco on January 25, 2020. All five evaluable patients showed tumor regression (100% response), clinical benefit and a reduction in mutated KRAS burden. Five different KRAS mutations were targeted by onvansertib, which accounts for more than 90% of all…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Trovagene (TROV) – Emerging as a Leader in Race to Develop KRAS Inhibitor

Posted on by Admin

Tuesday, January 28, 2020

Trovagene (TROV)

Emerging as a Leader in Race to Develop KRAS Inhibitor

Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.

Cosme Ordonez, Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

We are resuming coverage of Trovagene after reassigning research coverage to a different analyst. The company yesterday released interim results from a Phase II clinical trial on the use of onvansertib for the treatment of metastatic colorectal cancer (CRC) patients carrying KRAS mutations. Onvansertib is an inhibitor of PLK1. In experimental models, the drug kills cancer cells harboring KRAS mutations…

Results were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) held in San Francisco on January 25, 2020. All five evaluable patients showed tumor regression (100% response), clinical benefit and a reduction in mutated KRAS burden. Five different KRAS mutations were targeted by onvansertib, which accounts for more than 90% of all…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research scorpio bulkers salt weakness takes a toll but rebound expected

Posted on by Admin

Tuesday, January 28, 2020

Scorpio Bulkers (SALT)

Weakness Takes A Toll, But Rebound Expected

Scorpio Bulkers Inc is a shipping company based in Monaco. It owns and operates a fleet of modern mid to large-size dry bulk carriers which provide marine transportation for major bulks, which include iron ore, coal and grain and minor bulks which include bauxite, fertilizers and steel products internationally. In terms of its dead weight tonnage, its vessels are classified as Capesize, Kamsarmax and Ultramax, by the order of highest to lowest capacity, with Kamsarmax accounting for the highest revenue.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Adjusted 4Q2019 EBITDA of $20.0 million well below expectations. The main reasons for the negative variance were lower TCE rates, higher opex/G&A expenses and higher downtime for scrubber installations. Non-cash items include gain in STNG investment of $47 million and asset write down of $25 million.

Dry bulk market weakness accelerating into 1Q2020. The Baltic Panamax Index (BPI) average of 814 so far in 1Q2020 is down 52% from 1,461 in 4Q2019, and the Baltic Supramax Index (BSI) average of 542 so far in 1Q2020 is down 43% from 956 in 4Q2019. While IMO2020 adjustments to the indices have been partially to blame, the dry bulk market has clearly been weaker than expected and…


Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Scorpio Bulkers (SALT) – Weakness Takes A Toll, But Rebound Expected

Posted on by Admin

Tuesday, January 28, 2020

Scorpio Bulkers (SALT)

Weakness Takes A Toll, But Rebound Expected

Scorpio Bulkers Inc is a shipping company based in Monaco. It owns and operates a fleet of modern mid to large-size dry bulk carriers which provide marine transportation for major bulks, which include iron ore, coal and grain and minor bulks which include bauxite, fertilizers and steel products internationally. In terms of its dead weight tonnage, its vessels are classified as Capesize, Kamsarmax and Ultramax, by the order of highest to lowest capacity, with Kamsarmax accounting for the highest revenue.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Adjusted 4Q2019 EBITDA of $20.0 million well below expectations. The main reasons for the negative variance were lower TCE rates, higher opex/G&A expenses and higher downtime for scrubber installations. Non-cash items include gain in STNG investment of $47 million and asset write down of $25 million.

Dry bulk market weakness accelerating into 1Q2020. The Baltic Panamax Index (BPI) average of 814 so far in 1Q2020 is down 52% from 1,461 in 4Q2019, and the Baltic Supramax Index (BSI) average of 542 so far in 1Q2020 is down 43% from 956 in 4Q2019. While IMO2020 adjustments to the indices have been partially to blame, the dry bulk market has clearly been weaker than expected and…


Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Impact Investing Challenges Traditional Methods for Promoting Social Good

Posted on by Admin

Impact Investing Challenges Traditional Methods for Promoting Social Good

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

Impact investing is a strategy to invest in companies, organizations and funds with the intention to generate a positive social or environmental impact while earning a financial return.  Impact investing challenges the view that social and environmental issues should only be addressed by charitable donations, and that financial investments should focus only on returns.  The Global Impact Investing Network (GIIN) estimates that over 1,340 organizations managed US$502 billion in impact investing assets worldwide in 2018 and these numbers are expected to grow.  Alternative asset managers are starting funds dedicated to meeting environmental, social and governance targets as they seek to diversify product offerings, increase fees and meet growing demand from investors.

Long Story Short: Impact Investing – Doing Well by Doing Good

Posted on by Admin

Impact Investing Challenges Traditional Methods for Promoting Social Good

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

Impact investing is a strategy to invest in companies, organizations and funds with the intention to generate a positive social or environmental impact while earning a financial return.  Impact investing challenges the view that social and environmental issues should only be addressed by charitable donations, and that financial investments should focus only on returns.  The Global Impact Investing Network (GIIN) estimates that over 1,340 organizations managed US$502 billion in impact investing assets worldwide in 2018 and these numbers are expected to grow.  Alternative asset managers are starting funds dedicated to meeting environmental, social and governance targets as they seek to diversify product offerings, increase fees and meet growing demand from investors.

Research kratos defense security ktos are recent headlines a harbinger of things to come

Posted on by Admin

Monday, January 27, 2020

Kratos Defense & Security (KTOS)

Are Recent Headlines a Harbinger of Things to Come?

Kratos Defense & Security Solutions is a National Security technology provider with proprietary expertise in the area of unmanned aerial vehicles, electronics for missile defense systems, electronic warfare systems, satellite control and management systems and support services for emerging naval weapon systems. Commercial and state and local government revenues are about 25% of the total and comprise primarily of critical infrastructure monitoring and protection systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

More Positive Headlines.  In a recurring, almost weekly, theme, Kratos continues to see positive developments across a broad swath of its business. This past week, Kratos saw what we view as positive developments in both its Gremlins and Skyborg programs. While a leading independent, non-partisan policy research institute reaffirmed the need for Kratos’s products.

Successful Gremlins Test. DARPA’s Gremlins program completed the first flight test of its X-61A vehicle, built by Kratos. Kratos partners with Dynectics on this program which seeks to launch swarm UASs from multiple types of aircraft. The November test met all of its objectives. Another test…



Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision. 

Research – Kratos Defense & Security (KTOS) – Are Recent Headlines a Harbinger of Things to Come?

Posted on by Admin

Monday, January 27, 2020

Kratos Defense & Security (KTOS)

Are Recent Headlines a Harbinger of Things to Come?

Kratos Defense & Security Solutions is a National Security technology provider with proprietary expertise in the area of unmanned aerial vehicles, electronics for missile defense systems, electronic warfare systems, satellite control and management systems and support services for emerging naval weapon systems. Commercial and state and local government revenues are about 25% of the total and comprise primarily of critical infrastructure monitoring and protection systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

More Positive Headlines.  In a recurring, almost weekly, theme, Kratos continues to see positive developments across a broad swath of its business. This past week, Kratos saw what we view as positive developments in both its Gremlins and Skyborg programs. While a leading independent, non-partisan policy research institute reaffirmed the need for Kratos’s products.

Successful Gremlins Test. DARPA’s Gremlins program completed the first flight test of its X-61A vehicle, built by Kratos. Kratos partners with Dynectics on this program which seeks to launch swarm UASs from multiple types of aircraft. The November test met all of its objectives. Another test…



Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.